1. Home
  2. TLIH vs ERNA Comparison

TLIH vs ERNA Comparison

Compare TLIH & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TLIH

Ten-League International Holdings Limited Ordinary Shares

HOLD

Current Price

$4.11

Market Cap

7.1M

Sector

N/A

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

BUY

Current Price

$9.12

Market Cap

5.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
TLIH
ERNA
Founded
1998
2018
Country
Singapore
United States
Employees
62
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
5.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TLIH
ERNA
Price
$4.11
$9.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
125.6K
4.1M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.13
52 Week High
$7.00
$15.88

Technical Indicators

Market Signals
Indicator
TLIH
ERNA
Relative Strength Index (RSI) 75.25 54.93
Support Level $0.34 $0.61
Resistance Level $4.65 $15.88
Average True Range (ATR) 0.32 2.47
MACD -0.05 -0.40
Stochastic Oscillator 97.76 24.25

Price Performance

Historical Comparison
TLIH
ERNA

About TLIH Ten-League International Holdings Limited Ordinary Shares

Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: